Fiche centre
University of Washington Medical Center
Seattle — United States
Essais liés9clinical trials
VilleSeattlelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06643481
Essais cliniques associés
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT05151471 | Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS | TERMINATED |
| PF-07799544 | Cancer | Phase 1 | NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | RECRUITING |
| VHB937 | Sclérose latérale amyotrophique | Phase 2 | NCT06643481 | ASTRALS — A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) | ACTIVE_NOT_RECRUITING |
| Acoramidis | Alzheimer | Phase 3 | NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | RECRUITING |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT04165824 | Safety Study of Oral Edaravone Administered in Subjects With ALS | COMPLETED |
| Deep Brain Stimulation (DBS) | Parkinson | À vérifier | NCT02071134 | Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | RECRUITING |
| AB-1003 dose level 1 | Myopathies | Phase 1/2 | NCT05230459 | A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1) | ACTIVE_NOT_RECRUITING |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT04569084 | Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS | TERMINATED |
| IGIV-C | Myasthénie | Phase 2 | NCT02473965 | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis | COMPLETED |